Changeflow GovPing Healthcare & Life Sciences EPO Grants EP3799568A1 to Oregon Health & Scien...
Routine Notice Added Final

EPO Grants EP3799568A1 to Oregon Health & Science University for Anti-AAV2 Capsid Antibody Epitopes

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office granted Patent EP3799568A1 to Oregon Health & Science University on April 15, 2026, covering human anti-AAV2 capsid polyclonal antibody epitopes. The patent names three inventors: ADACHI Kei, CHANG Xiao Lan, and NAKAI Hiroyuki. The designated contracting states cover all EU member states plus associated countries including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR. This represents a confirmed patent grant for gene therapy vector research, with the invention classified under IPC codes A61K, C07K, and C12N.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 46 changes logged to date.

What changed

The European Patent Office granted Patent EP3799568A1, a first-publication (A1) European patent application covering human anti-AAV2 capsid polyclonal antibody epitopes. This represents a confirmed grant of exclusivity for the applicant Oregon Health & Science University across all designated EU contracting states.

For manufacturers and researchers in the gene therapy or AAV vector space, this patent establishes intellectual property protection around specific capsid antibody epitopes. Competitors developing similar immunogenic mapping or antibody screening technologies against AAV2 may need to evaluate freedom-to-operate implications. The patent's broad designated state coverage means protection extends across all listed European jurisdictions simultaneously.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

HUMAN ANTI-AAV2 CAPSID POLYCLONAL ANTIBODY EPITOPES

Publication EP3799568A1 Kind: A1 Apr 15, 2026

Applicants

Oregon Health & Science University

Inventors

ADACHI, Kei, CHANG, Xiao Lan, NAKAI, Hiroyuki

IPC Classifications

A61K 35/76 20150101AFI20220602BHEP A61K 35/761 20150101ALI20220602BHEP A61K 39/235 20060101ALI20220602BHEP C07K 14/005 20060101ALI20220602BHEP C12N 15/09 20060101ALI20220602BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3799568A1

Who this affects

Applies to
Manufacturers Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Gene therapy research Biopharmaceutical IP
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!